Posters
« Back
DOSTARLIMAB : A BREAKTHROUGH IN THE FIELD OF CANCER
EP39630
Poster Title: DOSTARLIMAB : A BREAKTHROUGH IN THE FIELD OF CANCER
Submitted on 09 Dec 2022
Author(s): sriram Praveen*,G.mohana chari
Affiliations:
Poster Views: 311
View poster »


Poster Information
Abstract:

ABSTRACT
Cancer,a disease where uncontrollable cells grow and invasion to other parts of the body is observed. Cancer a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020 and nearly one among six deaths in the world. In 2020, the most common cancer cancers are breast cancer (2.26million cases), colorectal cancer (1.93million cases) , prostate cancer(1.41million) and lung cancers(2.21million cases). More than 200 types of cancers were classified according to their site of origin .
Chemotherapy widely used for cancer treatment widely employs Durvalumab,Atezolizumab, Nivolumab,Pembrolizumab,and Avelumab with adverse effects.
DOSTARLIMAB, a FDA approved drug widely prescribed for endometrial cancers that acts in accordance with other programmed death ligand-1or programmed death-1 (PD-L1/PD-1) It is a humanized monoclonal antibody that binds with high affinity to PD-1,resulting in inhibition of binding to PD-L1 and Programmed death ligand-2(PD-L2). It is used as an immunotherapy drug for treating cancer.
A monoclonal antibody is a type of protein that is particularly produced in a laboratory to serve as substitute antibodies that can imitate the immune system. Strikes on the cells that are unwanted such as cancer cells. Dostarlimab cures 100% of the colorectal cancer (CRC) patients who are given this drug with minimal adverse events of grade 3 or higher in any patient.
Keywords- Cancer, Dostarlimab, Immunotherapy.





Summary: Cancer a disease where uncontrollable cells grow and invasion to other partsReferences: https://www.nih.gov/about-nih/what-we-do/nih-almanac/national-cancer-institute-nci
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors
Report abuse »
Creative Commons